Cáncer metastásico con primario desconocido. Una revisión

  • Laura Rodríguez Universidad Nacional de Colombia
  • William Otero Regino Universidad Nacional de Colombia
  • Fabio Grosso Instituto Nacional de cancerología
Palabras clave: tumor metastásico, primario desconocido, cáncer

Resumen

El tumor metastásico no siempre tiene un origen evidente, hasta en un tercio de los casos nunca se encuentra el tumor primario. Este artículo es una guía de los avances más recientes para mejorar el enfoque diagnóstico y el manejo del paciente, con este fatal y frecuente tumor. El objetivo de este articulo, además de ser una guía, es ayudar a evitar errores comunes y graves. Uno de los errores más importantes es no tener en cuenta el papel fundamental de la confirmación histológica, pues esta puede evitar investigaciones innecesarias.En el articulo también se detallan los componentes de la evaluación estándar, la clasificación según su pronóstico y las indicaciones de la evaluación secundaria, que incluye las indicaciones de la endoscopia alta y baja, los marcadores tumorales, la tomografía por emisión de positrones, el papel que ocupa el perfil genético, la epigenética y el ADN viral. Por otro lado, se indica el momento en que se debe detener la investigación. Recientemente, el tratamiento se ha modificado y con ello parece cambiar la historia de estos pacientes y de sus contrapartes con primario conocido

Biografía del autor/a

Laura Rodríguez, Universidad Nacional de Colombia
Médico UNAL
William Otero Regino, Universidad Nacional de Colombia
Profesor de medicina, Unidad de gastroenterología, Universidad Nacional de Colombia
Fabio Grosso, Instituto Nacional de cancerología
Internista Oncólogo, Instituto Nacional de Cancerología, Universidad El Bosque, Centro Nacional de Oncología. Bogotá, Colombia

Citas

Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet (London, England). 2012;379(9824):1428-35.

https://doi.org/10.1016/S0140-6736(11)61178-1

Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M, et al. Unknown primary tumors. Biochimica et biophysica acta. 2011;1816(1):13-24.

https://doi.org/10.1016/j.bbcan.2011.02.002

Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: population-based analysis by site and histology. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(7):1854-63.

https://doi.org/10.1093/annonc/mdr536

Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. European journal of cancer (Oxford, England : 1990). 2007;43(14):2026-36.

https://doi.org/10.1016/j.ejca.2007.06.023

Kim KW, Krajewski KM, Jagannathan JP, Nishino M, Shinagare AB, Hornick JL, et al. Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. AJR American journal of roentgenology. 2013;200(3):484-92.

https://doi.org/10.2214/AJR.12.9363

Moran S, Martinez-Cardus A, Boussios S, Esteller M. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nature reviews Clinical oncology. 2017.

https://doi.org/10.1038/nrclinonc.2017.97

Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, et al. How to Diagnose and Treat a Cancer of Unknown Primary Site. Journal of gastrointestinal and liver diseases : JGLD. 2017;26(1):69-79.

Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. European journal of cancer (Oxford, England : 1990). 2003;39(14):1990-2005.

https://doi.org/10.1016/S0959-8049(03)00547-1

Swaid F, Downs D, Rosemurgy AS. A practical approach to liver metastasis from unknown primary cancer: What surgeons need to know. Cancer genetics. 2016;209(12):559-66.

https://doi.org/10.1016/j.cancergen.2016.08.004

Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Critical reviews in oncology/hematology. 2009;69(3):271-8.

https://doi.org/10.1016/j.critrevonc.2008.09.005

Hemminki K, Pavlidis N, Tsilidis KK, Sundquist K, Ji J. Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model. Scientific reports. 2016;6:23725.

https://doi.org/10.1038/srep23725

Hemminki K, Chen B, Melander O, Manjer J, Hallmans G, Hemminki A. Smoking and body mass index as risk factors for subtypes of cancer of unknown primary. International journal of cancer. 2015;136(1):246-7.

https://doi.org/10.1002/ijc.28969

MacReady N. NICE issues guidance on cancer of unknown primary. The Lancet Oncology. 2010;11(9):824.

https://doi.org/10.1016/S1470-2045(10)70215-1

Collado Martin R, Garcia Palomo A, de la Cruz Merino L, Borrega Garcia P, Baron Duarte FJ. Clinical guideline SEOM: cancer of unknown primary site. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2014;16(12):1091-7.

https://doi.org/10.1007/s12094-014-1244-0

Greco FA. Cancer of unknown primary site: improved patient management with molecular and immunohistochemical diagnosis. American Society of Clinical Oncology educational book American Society of Clinical Oncology Meeting. 2013:175-81.

https://doi.org/10.1200/EdBook_AM.2013.33.175

Varadhachary GR, Raber MN. Cancer of unknown primary site. The New England journal of medicine. 2014;371(8):757-65.

https://doi.org/10.1056/NEJMra1303917

Muller von der Grun J, Tahtali A, Ghanaati S, Rodel C, Balermpas P. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges. 2017;12(1):82.

Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin--diagnosis and treatment. Nature reviews Clinical oncology. 2011;8(12):701-10.

https://doi.org/10.1038/nrclinonc.2011.158

Vajdic CM, Goldstein D. Cancer of unknown primary site. Australian family physician. 2015;44(9):640-3.

Kamposioras K, Pentheroudakis G, Pavlidis N. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. European journal of clinical investigation. 2013;43(5):491-500.

https://doi.org/10.1111/eci.12062

Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. The oncologist. 2009;14(12):1189-97.

https://doi.org/10.1634/theoncologist.2009-0112

Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA oncology. 2015;1(1):40-9.

https://doi.org/10.1001/jamaoncol.2014.216

Loffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016;7(28):44322-9.

https://doi.org/10.18632/oncotarget.10035

Stella GM, Senetta R, Cassenti A, Ronco M, Cassoni P. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. Journal of translational medicine. 2012;10:12.

https://doi.org/10.1186/1479-5876-10-12

Pavlidis N, Khaled H, Gaafar R. A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. Journal of advanced research. 2015;6(3):375-82.

https://doi.org/10.1016/j.jare.2014.11.007

Pavlidis N, Petrakis D, Golfinopoulos V, Pentheroudakis G. Long-term survivors among patients with cancer of unknown primary. Critical reviews in oncology/hematology. 2012;84(1):85-92.

https://doi.org/10.1016/j.critrevonc.2012.02.002

Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26 Suppl 5:v133-8.

Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, et al. Occult primary, version 3.2014. Journal of the National Comprehensive Cancer Network : JNCCN. 2014;12(7):969-74.

https://doi.org/10.6004/jnccn.2014.0093

Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast cancer research and treatment. 2010;119(1):1-11.

https://doi.org/10.1007/s10549-009-0554-3

Fayanju OM, Jeffe DB, Margenthaler JA. Occult primary breast cancer at a comprehensive cancer center. The Journal of surgical research. 2013;185(2):684-9.

https://doi.org/10.1016/j.jss.2013.06.020

Jentsch-Ullrich K, Kalinski T, Roessner A, Franke A, Mohren M. Long-term remission in a patient with carcinoma of unknown primary site. Chemotherapy. 2006;52(1):12-5.

https://doi.org/10.1159/000090235

Lanzer M, Bachna-Rotter S, Graupp M, Bredell M, Rucker M, Huber G, et al. Unknown primary of the head and neck: A long-term follow-up. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery. 2015;43(4):574-9.

https://doi.org/10.1016/j.jcms.2015.03.004

Eldeeb H, Hamed RH. Squamous cell carcinoma metastatic to cervical lymph nodes from unknown primary origin: the impact of chemoradiotherapy. Chinese journal of cancer. 2012;31(10):484-90.

https://doi.org/10.5732/cjc.012.10035

Pentheroudakis G, Stoyianni A, Pavlidis N. Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis? Cancer treatment reviews. 2011;37(2):120-6.

https://doi.org/10.1016/j.ctrv.2010.06.003

Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Critical reviews in oncology/hematology. 2010;75(1):27-42.

https://doi.org/10.1016/j.critrevonc.2009.10.003

Economopoulou P, Pentheroudakis G. Cancer of unknown primary: time to put the pieces of the puzzle together? The Lancet Oncology. 2016;17(10):1339-40.

https://doi.org/10.1016/S1470-2045(16)30377-1

Saliminejad M, Bemanian S, Ho A, Spiegel B, Laine L. The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary. Alimentary pharmacology & therapeutics. 2013;38(6):628-33.

https://doi.org/10.1111/apt.12429

Mackenzie K, Watson M, Jankowska P, Bhide S, Simo R. Investigation and management of the unknown primary with metastatic neck disease: United Kingdom National Multidisciplinary Guidelines. The Journal of laryngology and otology. 2016;130(S2):S170-s5.

https://doi.org/10.1017/S0022215116000591

Tan S, David J, Lalonde L, El Khoury M, Labelle M, Younan R, et al. Breast magnetic resonance imaging: are those who need it getting it? Current oncology (Toronto, Ont). 2017;24(3):e205-e13.

https://doi.org/10.3747/co.24.3441

Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2013;25(4):e33-66.

Rudmik L, Lau HY, Matthews TW, Bosch JD, Kloiber R, Molnar CP, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head & neck. 2011;33(7):935-40.

https://doi.org/10.1002/hed.21566

Karapolat I, Kumanlioglu K. Impact of FDG-PET/CT for the Detection of Unknown Primary Tumours in Patients with Cervical Lymph Node Metastases. Molecular imaging and radionuclide therapy. 2012;21(2):63-8.

https://doi.org/10.4274/Mirt.344

Sharma P, Arora S, Mukherjee A, Pal S, Sahni P, Garg P, et al. Predictive value of 68Ga-DOTANOC PET/CT in patients with suspicion of neuroendocrine tumors: is its routine use justified? Clinical nuclear medicine. 2014;39(1):37-43.

https://doi.org/10.1097/RLU.0000000000000257

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(6):588-96.

https://doi.org/10.1200/JCO.2015.64.0987

Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. European journal of nuclear medicine and molecular imaging. 2010;37(1):67-77.

https://doi.org/10.1007/s00259-009-1205-y

Conner JR, Hornick JL. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry. Advances in anatomic pathology. 2015;22(3):149-67.

https://doi.org/10.1097/PAP.0000000000000069

Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Applied immunohistochemistry & molecular morphology : AIMM. 2010;18(1):3-8.

https://doi.org/10.1097/PAI.0b013e3181a75e6d

Greco FA. The impact of molecular testing on treatment of cancer of unknown primary origin. Oncology (Williston Park, NY). 2013;27(8):815-7.

Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005;11(10):3766-72.

https://doi.org/10.1158/1078-0432.CCR-04-2236

Kandalaft PL, Gown AM. Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site. Archives of pathology & laboratory medicine. 2016;140(6):508-23.

https://doi.org/10.5858/arpa.2015-0173-CP

Chiang WM, Kapadia M, Laver NV, Nystrom JS. Cancer of unknown primary: from immunohistochemistry to gene expression profiling. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(29):e300-2.

https://doi.org/10.1200/JCO.2011.41.1827

Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer treatment reviews. 2009;35(7):570-3.

https://doi.org/10.1016/j.ctrv.2009.05.005

Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. Critical reviews in oncology/hematology. 2012;84(2):213-23.

https://doi.org/10.1016/j.critrevonc.2012.03.003

Gaertner J, Weingartner V, Lange S, Hausner E, Gerhardus A, Simon ST, et al. The Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature Review. PloS one. 2015;10(9):e0136640.

https://doi.org/10.1371/journal.pone.0136640

Greco FA. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management. Current treatment options in oncology. 2013;14(4):634-42.

https://doi.org/10.1007/s11864-013-0257-1

Takagi T, Katagiri H, Kim Y, Suehara Y, Kubota D, Akaike K, et al. Skeletal Metastasis of Unknown Primary Origin at the Initial Visit: A Retrospective Analysis of 286 Cases. PloS one. 2015;10(6).

https://doi.org/10.1371/journal.pone.0129428

Publicado
2018-07-05
Sección
Revisión de tema